↓ Skip to main content

Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival

Overview of attention for article published in Breast Cancer Research, June 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#32 of 1,860)
  • High Attention Score compared to outputs of the same age (97th percentile)

Mentioned by

news
8 news outlets
blogs
1 blog
twitter
52 tweeters
facebook
2 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
54 Dimensions

Readers on

mendeley
92 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival
Published in
Breast Cancer Research, June 2017
DOI 10.1186/s13058-017-0870-1
Pubmed ID
Authors

Jan Poleszczuk, Kimberly Luddy, Lu Chen, Jae K. Lee, Louis B. Harrison, Brian J. Czerniecki, Hatem Soliman, Heiko Enderling

Abstract

Compared with surgery alone, postoperative adjuvant radiotherapy (RT) improves relapse-free survival of patients with early-stage breast cancer. We evaluated the long-term overall and disease-free survival rates of neoadjuvant (presurgical) versus adjuvant RT in early-stage breast cancer patients. We used the Surveillance, Epidemiology, and End Results (SEER) database provided by the National Institutes of Health to derive an analytic dataset of 250,195 female patients with early-stage breast cancer who received RT before (n = 2554; 1.02%) or after (n = 247,641; 98.98%) surgery. Disease-free survival, defined as time to diagnosis of a second primary tumor at any location, was calculated from automated patient identification matching of all SEER records. Partial and complete mastectomies were performed in 94.4% and 5.6% of patients, respectively. In the largest cohort of estrogen receptor-positive women who underwent partial mastectomy, the HR of developing a second primary tumor after neoadjuvant compared with adjuvant RT was 0.64 (95% CI 0.55-0.75; P < 0.0001). Overall survival was independent of radiation sequence (HR 1; P = 0.95). Neoadjuvant RT also resulted in a lower HR for second primary cancer among estrogen receptor-positive patients who underwent mastectomy compared with those who received adjuvant RT (HR 0.48, 95% CI 0.26-0.87; P = 0.0162). Neoadjuvant RT may significantly improve disease-free survival without reducing overall survival, especially for estrogen receptor-positive patients with early-stage breast cancer. This finding warrants further exploration of potential long-term benefits of neoadjuvant radiotherapy for early-stage breast cancer in a controlled, prospective clinical trial setting, with correlative studies done to identify potential mechanisms of superiority.

Twitter Demographics

The data shown below were collected from the profiles of 52 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 92 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 16 17%
Student > Bachelor 13 14%
Student > Ph. D. Student 10 11%
Researcher 9 10%
Other 7 8%
Other 18 20%
Unknown 19 21%
Readers by discipline Count As %
Medicine and Dentistry 40 43%
Biochemistry, Genetics and Molecular Biology 8 9%
Agricultural and Biological Sciences 8 9%
Nursing and Health Professions 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 8 9%
Unknown 21 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 98. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2019.
All research outputs
#343,180
of 22,012,190 outputs
Outputs from Breast Cancer Research
#32
of 1,860 outputs
Outputs of similar age
#8,173
of 286,261 outputs
Outputs of similar age from Breast Cancer Research
#1
of 3 outputs
Altmetric has tracked 22,012,190 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,860 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,261 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them